{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:35:49Z","timestamp":1758818149669},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03891-9","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T12:02:07Z","timestamp":1702209727000},"page":"1559-1563","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of intradetrusor onabotulinum toxin A efficacy and safety in older adults with urge urinary incontinence"],"prefix":"10.1007","volume":"56","author":[{"given":"Michael F.","family":"Basin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyal","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasija","family":"Useva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Ginzburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"3891_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"key":"3891_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","volume":"11","author":"WS Reynolds","year":"2016","unstructured":"Reynolds WS, Fowke J, Dmochowski R (2016) The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep 11:8","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"3891_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000351037","volume":"91","author":"Y Cui","year":"2013","unstructured":"Cui Y et al (2013) Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int 91:429\u2013438","journal-title":"Urol Int"},{"key":"3891_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"3891_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306\u20131315","journal-title":"Eur Urol"},{"key":"3891_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196\u2013200","journal-title":"J Urol"},{"key":"3891_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1023\/A:1015570104121","volume":"24","author":"HJM Beijer","year":"2002","unstructured":"Beijer HJM, De Blaey CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 24:46\u201354","journal-title":"Pharm World Sci"},{"key":"3891_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jppr.1303","volume":"47","author":"L Kouladjian O\u2019Donnell","year":"2017","unstructured":"Kouladjian O\u2019Donnell L, Gnjidic D, Nahas R, Bell JS, Hilmer SN (2017) Anticholinergic burden: considerations for older adults. J Pharm Pract Res 47:67\u201377","journal-title":"J Pharm Pract Res"},{"key":"3891_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/nau.21021","volume":"30","author":"E Rovner","year":"2011","unstructured":"Rovner E et al (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30:556\u2013562","journal-title":"Neurourol Urodyn"},{"key":"3891_CR10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416\u20132422","journal-title":"J Urol"},{"key":"3891_CR11","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186\u20132193","journal-title":"J Urol"},{"key":"3891_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","volume":"103","author":"A Sahai","year":"2009","unstructured":"Sahai A, Dowson C, Khan MS, Dasgupta P (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509\u20131515","journal-title":"BJU Int"},{"key":"3891_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/0970-1591.109975","volume":"29","author":"B Orasanu","year":"2013","unstructured":"Orasanu B, Mahajan ST (2013) The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol 29:2","journal-title":"Indian J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03891-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T12:09:06Z","timestamp":1712578146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03891-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03891-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,10]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}